𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of Cutaneous T Cell Lymphoma Stage II with Interferon-α-2a and Extracorporeal Photochemotherapy : A Prospective Controlled Trial

✍ Scribed by U. WOLLINA; A. LOOKS; J. MEYER; B. KNOPF; H.-J. KOCH; K. LIEBOLD; U.-C. HIPLER

Book ID
111396977
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
172 KB
Volume
941
Category
Article
ISSN
0890-6564

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of interferon-α-2a plus p
Phase II trial of interferon-α-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma
✍ Vanna Chiarion-Sileni; Antonio Bononi; Cleto Veller Fornasa; Mariella Soraru; Ma 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

## Purpose: To evaluate the efficacy and side effects of psolaren with ultraviolet light a (puva) and interferon-alpha-2a (ifn-alpha-2a) in patients with mycosis fungoides (mf) and sézary syndrome (ss). ## Patients and methods: From may 1993 to january 1999, 63 symptomatic patients with all stage

Results of a Phase II trial of oral bexa
Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma
✍ David J. Straus; Madeleine Duvic; Timothy Kuzel; Steven Horwitz; Marie-France De 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

## Abstract ## BACKGROUND. Bexarotene is one of the most active single agents for the treatment of recurring or refractory cutaneous T‐cell lymphoma (CTCL). Interferon alfa has also been used for many years as an effective treatment for this disease. The results in recent case reports of the combi